Software Asset Management - Oracle Frequently Asked Questions
Achieving cost reduction and control over your software estate is complex. We answer our customers' FAQs about Software Asset Management.
Adopting the correct approach and methodology will help you realise value for money and reduce the risk of non-compliance. From Version 1’s experience, we would consider the following FAQs about Oracle Software Asset Management as typical cost control issues when trying to manage a large Oracle license estate.
FAQs about Software Asset Management
We can assess the impact of outsourcing on your obligations under your Oracle software license agreements and identify opportunities and risks relating to the management of your Oracle estate.
We can work with your outsource provider to assess against best practice the methods by which they manage your Oracle software assets for you.
We can provide an assessment against our Capability Maturity Model which will give you a view of how your current practices measure up to best practice. We can also provide advise on how to make improvements where required.
We can assess whether your Oracle agreements are able to support changing business needs e.g. mergers and acquisitions, business expansion, internationalisation, outsourcing, etc.
We can assess your current use of Oracle E-Business Suite against a set of pre-defined metrics to determine your current product use.
Auto-discovery tools automate the majority of the data collection process reducing both the time and effort required to determine usage on large Oracle license estates. This approach has the additional benefit over a manual approach of repeatability, completeness and data consistency.
Our Discovery service can be used to determine current usage for the products within the scope of your ULA. This can then be used as the basis for your declaration to Oracle.
As an Oracle partner, we are able to act as an intermediary and help you to prepare usage information against an agreed set of metrics.
We can help you negotiate with Oracle to migrate to a simpler license model using fewer metrics.
We can identify areas of potential cost saving and/or cost avoidance and identify how we can help with further analysis
We can provide you with a fuller understanding of the opportunities to reduce the potential for compliance risks relating to your Oracle license estate.
We can identify areas of potential under/over-licensing that justify further analysis.
We can assess and advise on strategies to retire software licenses and/or reduce the number of licenses under support.
We can advise you on the implications and best use of central government purchasing frameworks with Oracle.
Why Version 1?
We will always put the customer first. We are technology agnostic, providing a modular plug & play approach to each set of unique customer requirements. We enable clients to make better, more informed decisions on their software estate; understand the options and make the right decision for you. Our priority is to give the best advice, not just to secure licensing revenue.
Reduce Cost & Risk
- Tools Agnostic
Market Leading Expertise
- Breadth & Scale
- Technical Background
- Ongoing Staff Education
82% financial risk reduction
Our optimisation expertise helps to deliver financial risk reduction of over 82% on average during audit scenarios.
£17m to £100k
When engaged our customer was facing a bill of £17m, but through our help this amount became £100k
£5.8m identified non compliance risks
During a typical review, we find non-compliance risks of over £5.8m
Market Leading Services
Licence Audit Consulting
SAM Managed Services
News & Insights
Blog: June 18, 2020
In this blog, Principal License Consultant, Karl O’Doherty, discusses the Microsoft Enterprise Agreement vs Cloud Solution Provider Program. Originally designed for on-premise software, the Microsoft...
Blog: May 5, 2020
The output of this exercise is known in the industry as an Effective License Position (ELP). Think of it this way; if ELP is the headache (which it can be), then License Optimisation is the medicine to...